Search Results

You are looking at 1 - 10 of 171 items for :

  • "neuropathy" x
Clear All
Full access

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn

References 1 Hausheer FH Schilsky RL Bain S . Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy . Semin Oncol 2006 ; 33 : 15 – 49 . 2 Langkjer ST Ejlertsen B Mouridsen H . Vinorelbine as

Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades and Kenneth Anderson

Peripheral neuropathy (PN) and asthenia (fatigue) are among the most commonly seen complications in patients undergoing multiple myeloma (MM) therapy. These potentially debilitating adverse effects are frequently dose limiting, and they may

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente and Francisco Ayala de la Peña

-line taxanes also improve progression-free and overall survival. 3 Although myelosuppression is the major toxicity for docetaxel, 4 paclitaxel is more likely to be associated with dose-limiting peripheral neuropathy. 3 Paclitaxel-induced peripheral

Full access

Charise Gleason, Ajay Nooka and Sagar Lonial

. Improved survival in multiple myeloma and the impact of novel therapies . Blood 2008 ; 111 : 2516 – 2520 . 2 Silberman J Lonial S . Review of peripheral neuropathy in plasma cell disorders . Hematol Oncol 2008 ; 26 : 55 – 65 . 3

Full access

Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard and Charles L. Loprinzi

Oxaliplatin-induced peripheral neuropathy is a common toxicity that may last for years, which has resulted in extensive interest in identifying interventions to prevent its occurrence. Administration of intravenous doses of calcium and magnesium

Full access

Noopur S. Raje, Andrew J. Yee and G. David Roodman

Hematology and UK Myeloma Forum. 8 This review focuses on advances in the management of bone-related complications, peripheral neuropathy, thrombosis, and risk of infection. Bone Complications Bone involvement is one of the pathognomonic and defining

Full access

7 7 Suppl_5 Suppl_5 NCCN Task Force Report: Management of Neuropathy in Cancer Stubblefield Michael D. MD Burstein Harold J. MD, PhD Burton Allen W. MD Custodio Christian M. MD Deng Gary E. MD, PhD Ho Maria PhD

Full access

J. Matt McCrary, David Goldstein, Terry Trinh, Hannah C. Timmins, Tiffany Li, Jasmine Menant, Michael Friedlander, Craig R. Lewis, Mark Hertzberg, Siobhan O’Neill, Tracy King, Annmarie Bosco, Michelle Harrison and Susanna B. Park

treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is a significant dose-limiting adverse effect of cancer treatment and is estimated to impact 68% of patients treated with neurotoxic chemotherapies, leading to functional disability and permanent

Full access

Elizabeth Kvale and Susan G. Urba

NCCN has expanded the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship to include a section on cancer-associated cognitive impairment and to include chemotherapy-induced peripheral neuropathy as a component of the

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa and Lois B. Travis

has been associated with cisplatin-induced tinnitus (rs7606353). 46 Neurotoxicity Approximately 20% to 40% of TCS report peripheral neuropathy after cisplatin-based chemotherapy, 41 , 47 with incidence directly related to cumulative cisplatin dose 41